Literature DB >> 8301154

Consensus interferon induces peak mRNA accumulation at lower concentrations than interferon-alpha 2a.

S B Klein1, L M Blatt, M W Taylor.   

Abstract

The biological activity of a novel recombinant interferon, r-metIFN-con1, which represents a consensus sequence of the most commonly appearing amino acids at each locus of 14 naturally occurring IFN-alpha s, was assessed and compared to that of IFN-alpha 2a. The increase in cellular mRNA levels for three IFN-inducible genes served as a quantitative measure of the effectiveness of the stimulation by each of the IFNs. Three cell lines were treated with equimolar amounts of two IFNs encompassing a 5 log range and mRNA was extracted at five different times after treatment. In all cases, r-metIFN-con1 produced mRNA increases at lower concentrations than IFN-alpha 2a. HLA-DR alpha mRNA, which is not affected by IFN-alpha in ME180 or Daudi cells, was also not affected by r-metIFN-con1. However, in Eskol cells, both IFNs effected an increase in HLA-DR alpha mRNA to similar levels. The r-metIFN-con1 was effective at approximately 10-fold lower molar concentrations. At effective concentrations (10-fold lower molar dose of r-metIFN-con1), both IFNs produced similar kinetics of accumulation of all three mRNAs tested. r-metIFN-con1 is therefore more effective than IFN-alpha 2a at the level of mRNA regulation as well as the antiviral and antiproliferative activities that have been reported previously.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8301154     DOI: 10.1089/jir.1993.13.341

Source DB:  PubMed          Journal:  J Interferon Res        ISSN: 0197-8357


  4 in total

1.  Antiviral response of HCV genotype 1 to consensus interferon and ribavirin versus pegylated interferon and ribavirin.

Authors:  Maria H Sjogren; Robert Sjogren; Michael F Lyons; Michael Ryan; John Santoro; Coleman Smith; K Rajender Reddy; Herbert Bonkovsky; Brooke Huntley; Sima Faris-Young
Journal:  Dig Dis Sci       Date:  2007-04-04       Impact factor: 3.199

Review 2.  Interferon alfacon-1: a review of its pharmacology and therapeutic efficacy in the treatment of chronic hepatitis C.

Authors:  E B Melian; G L Plosker
Journal:  Drugs       Date:  2001       Impact factor: 9.546

3.  U.S. multicenter pilot study of daily consensus interferon (CIFN) plus ribavirin for "difficult-to-treat" HCV genotype 1 patients.

Authors:  Samuel B Ho; Bashar Aqel; Eric Dieperink; Shanglei Liu; Lori Tetrick; Yngve Falck-Ytter; Charles DeComarmond; Coleman I Smith; Daniel P McKee; William Boyd; Clark C Kulig; Edmund J Bini; Marcos C Pedrosa
Journal:  Dig Dis Sci       Date:  2011-01-11       Impact factor: 3.199

Review 4.  Inflammation and repair in viral hepatitis C.

Authors:  Manuela G Neuman; Kevin Sha; Rustan Esguerra; Sam Zakhari; Robert E Winkler; Nir Hilzenrat; Jonathan Wyse; Curtis L Cooper; Devanshi Seth; Mark D Gorrell; Paul S Haber; Geoffrey W McCaughan; Maria A Leo; Charles S Lieber; Mihai Voiculescu; Eugenia Buzatu; Camelia Ionescu; Jozsef Dudas; Bernhard Saile; Giuliano Ramadori
Journal:  Dig Dis Sci       Date:  2008-06       Impact factor: 3.487

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.